Platelet count-agnostic methods of treating myelofibrosis

    公开(公告)号:US11963962B2

    公开(公告)日:2024-04-23

    申请号:US17266262

    申请日:2019-08-21

    CPC classification number: A61K31/5377 A61K9/0053 A61P35/00

    Abstract: Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109/L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.

    Medical product dispensing systems and methods

    公开(公告)号:US11094406B2

    公开(公告)日:2021-08-17

    申请号:US14492618

    申请日:2014-09-22

    Abstract: Methods and systems for transferring restricted distribution medical products to an over-the-counter general sales environment are provided. Methods and systems of dispensing non-prescription, behind-the-counter medical products from a vending machine in a general sales location are also provided. In some embodiments, methods and systems are provided for dispensing a medical product from a vending machine in a general sales location based, at least in part, on biometric data collected from the purchaser and, in some instances, based on self-selection and/or de-selection criteria, is provided. Further, methods and systems of switching prescription medical products to non-prescription, over-the-counter medical products are provided.

    Metered dose container
    6.
    发明授权

    公开(公告)号:US10172765B2

    公开(公告)日:2019-01-08

    申请号:US15102564

    申请日:2014-12-11

    Abstract: Aspects of the present invention are directed to a metered dose container. The container may comprise a body; a first barrier in contact with a base of the container and extending partially along the vertical axis of the body; a second barrier in contact with a top of the container and extending partially along with vertical axis of the body. The space between the first barrier and the second barrier preferably defines a loading chamber, the space between the second barrier and a front wall of the container preferably defines a dispensing chamber, and the space between a rear wall of the container and the first barrier preferably defines a storage chamber. The base preferably also comprises a depressible portion that can convert the container from a transit mode to a dispensing mode.

    Bottle cap
    9.
    外观设计

    公开(公告)号:USD826713S1

    公开(公告)日:2018-08-28

    申请号:US29596005

    申请日:2017-03-03

    Abstract: The design consists of the features of configuration, shape, ornamentation and pattern of the COMBINED BOTTLE AND CAP shown in solid lines in the drawings. The portions in stippled lines do not form part of the design.FIG. 1 is a top perspective view of the combined bottle and cap;FIG. 2 is a bottom perspective view of the combined bottle and cap;FIG. 3 is a front elevational view of the combined bottle and cap;FIG. 4 is a rear elevational view of the combined bottle and cap;FIG. 5 is a side elevational view of the combined bottle and cap;FIG. 6 is a side elevational view of the combined bottle and cap rotated 180 degrees from FIG. 5;FIG. 7 is a top plan view of the combined bottle and cap; andFIG. 8 is a bottom plan view of the combined bottle and cap.Drawings of the design are included.

Patent Agency Ranking